The role of the central nervous system in the pathogenesis of polycystic ovary syndrome

Minerva Ginecologica

Volumn 58, Issue 1, 2006, Pages 41-54

  Hayden, C J ^a   Balen, A H ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Central nervous system; Neuroendocrine; Polycystic ovary syndrome

Indexed keywords

ANDROGEN; DOPAMINE; ESTROGEN; FOLLITROPIN; GONADORELIN; GONADORELIN RECEPTOR; INSULIN; LEPTIN; LUTEINIZING HORMONE; NEUROPEPTIDE Y; NEUROTRANSMITTER; NORADRENALIN; OPIATE; PROGESTERONE;

CENTRAL NERVOUS SYSTEM; CONSENSUS; DISEASE CLASSIFICATION; EMBRYO DEVELOPMENT; FEMALE; HUMAN; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; NEUROENDOCRINE DISEASE; NEUROPATHOLOGY; NONHUMAN; OVARY POLYCYSTIC DISEASE; OVULATION; PUBERTY; PULSE GENERATOR; REVIEW; SEXUAL MATURATION;

FEMALE; HUMANS; HYPOTHALAMUS; OVARY; PITUITARY GLAND; POLYCYSTIC OVARY SYNDROME;

EID: 33645277628     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-7.
2. Schwanzel-Fukuda M, Pfaff DW. Origin of luteinizing hormone-releasing hormone neurons. Nature 1989;338: 161-4.
3. Silverman AJ, Jhamandas J, Renaud LP. Localization of luteinizing hormone-releasing hormone (LHRH) neurons that project to the median eminence. J Neurosci 1987;7:2312-9.
4. Goldsmith PC, Thind KK, Song TS, Kim EJ, Boggant JE. Locations of the neuroendocrine gonadotropin-releasing hormone neurons in the monkey hypothalamus by retrograde staining and immunostaining. J Neuroendocrinol 1990;2:157-68.
5. Knobil E. The neuroendocrine control of the menstrual cycle. Recent Prog Horm Res 1980;36:53-88.
6. Van Vugt DA, Diefenbach WD, Alston E, Ferin M. Gonadotropin-releasing hormone pulses in third ventricular cerebrospinal fluid of ovariectomized rhesus monkeys: correlation with luteinizing hormone pulses. Endocrinology 1985;117:1550-8.
7. Backstrom CT, McNeilly AS, Leask RM, Baird DT. Pulsatile secretion of LH, FSH, prolactin, oestradiol and progesterone during the human menstrual cycle. Clin Endocrinol (Oxf) 1982;17:29-42.
8. Wildt L, Hausler A, Marshall G, Hutchison JS, Plant TM, Belchetz PE et al. Frequency and amplitude of gonadotropin-releasing hormone stimulation and gonadotropin secretion in the rhesus monkey. Endocrinology 1981;109:376-85.
9. Dalkin AC, Haisenleder DJ, Gilrain JT, Aylor K, Yasin M, Marshall JC. Gonadotropin-releasing hormone regulation of gonadotropin subunit gene expression in female rats: actions on follicle-stimulating hormone beta messenger ribonucleic acid (mRNA) involve differential expression of pituitary activin (beta-B) and follistatin mRNAs. Endocrinology 1999;140:903-8.
10. Rasmussen DD, Gambacciani M, Swartz W, Tueros VS, Yen SS. Pulsatile gonadotropin-releasing hormone release from the human mediobasal hypothalamus in vitro: opiate receptor-mediated suppression. Neuroendocrinology 1989;49:150-6.
11. Rossmanith WG, Liu CH, Laughlin GA, Mortola JF, Suh BY, Yen SS. Relative changes in LH pulsatility during the menstrual cycle: using data from hypogonadal women as a reference point. Clin Endocrinol (Oxf) 1990;32:647-60.
12. Andersen AN, Hagen C, Lange P, Boesgaard S, Djursing H, Eldrup E et al. Dopaminergic regulation of gonadotropin levels and pulsatility in normal women. Fertil Steril 1987;47:391-7.
13. Quigley ME, Rakoff JS, Yen SS. Increased luteinizing hormone sensitivity to dopamine inhibition in polycystic ovary syndrome. J Clin Endocrinol Metab 1981;52: 231-4.
14. Herbison AE. Noradrenergic regulation of cyclic GnRH secretion. Rev Reprod 1997;2:1-6.
15. Sahu A, Phelps CP, White JD, Crowley WK, Kalra SP, Kalra PS. Steroidal regulation of hypothalamic neuropeptide Y release and gene expression. Endocrinology 1992;130:3331-6.
16. Pau KY, Berria M, Hess DL, Spies HG. Hypothalamic site-dependent effects of neuropeptide Y on gonadotropin-releasing hormone secretion in rhesus macaques. J Neuroendocrinol 1995;7:63-7.
17. McShane TM, May T, Miner JL, Keisler DH. Central actions of neuropeptide-Y may provide a neuromodulatory link between nutrition and reproduction. Biol Reprod 1992;46:1151-7.
18. Rossmanith WG, Wirth U, Sterzik K, Yen SS. The effects of prolonged opioidergic blockade on LH pulsatile secretion during the menstrual cycle. J Endocrinol Invest 1989;12:245-52.
19. Suh BY, Liu JH, Berga SL, Quigley ME, Laughlin GA, Yen SS. Hypercortisolism in patients with functional hypothalamic-amenorrhea. I Clin Endocrinol Metab 1988;66:733-9.
20. Cumming DC, Reid RL, Quigley ME, Rebar RW, Yen SS. Evidence for decreased endogenous dopamine and opioid inhibitory influences on LH secretion in polycystic ovary syndrome. Clin Endocrinol (Oxf) 1984;20: 043-8.
21. Soules MR, Steiner RA, Clifton DK, Cohen NL, Aksel S, Bremner WJ. Progesterone modulation of pulsatile luteinizing hormone secretion in normal women. J Clin Endocrinol Metab 1984;58:378-83.
22. Wardlaw SL, Wehrenberg WB, Ferin M, Antunes JL, Frantz AG. Effect of sex steroids on beta-endorphin in hypophyseal portal blood. J Clin Endocrinol Metab 1982;55:877-81.
23. Goodman RL, Bittman EL, Foster DL, Karsch FJ. The endocrine basis of the synergistic suppression of luteinizing hormone by estradiol and progesterone. Endocrinology 1981;109:1414-7.
24. Romano GJ, Krust A, Pfaff DW. Expression and estrogen regulation of progesterone receptor mRNA in neurons of the mediobasal hypothalamus: an in situ hybridization study. Mol Endocrinol 1989;3:1295-300.
25. Maruncic M, Casper RF. The effect of luteal phase estrogen antagonism on luteinizing hormone pulsatility and luteal function in women. J Clin Endocrinol Metab 1987;64:148-52.
26. Huhtaniemi IT; Warren DW. Ontogeny of pituitary gonadal interactions: current advances and controversies. Trends Endocrinol Metab 1990;1:356-62.
27. Tse A, Hille B. GnRH-induced Ca2+ oscillations and rhythmic hyperpolarizations of pituitary gonadotropes. Science 1992;255:462-4.
28. Wang CF, Lasley BL, Lein A, Yen SS. The functional changes of the pituitary gonadotrophs during the menstrual cycle. J Clin Endocrinol Metab 1976;42:718-28.
29. Keen KL, Burich AJ, Mitsushima D, Kasuya E, Terasawa E. Effects of pulsatile infusion of the GABA(A) receptor blocker bicuculline on the onset of puberty in female rhesus monkeys. Endocrinology 1999;140: 5257-66.
30. El Majdoubi M, Sahu A, Ramaswamy S, Plant TM. Neuropeptide Y. A hypothalamic brake restraining the onset of puberty in primates. Proc Natl Acad Sci USA 2000;97:6179-84.
31. Clark PA, Iranmanesh A, Veldhuis JD, Rogol AD. Comparison of pulsatile luteinizing hormone secretion between prepubertal children and young adults: evidence for a mass/amplitude-dependent difference without gender or day/night contrasts. J Clin Endocrinol Metab 1997;82:2950-5.
32. Oerter KK, Uriarte MM, Rose SR, Barnes KM, Cutler GB Jr. Gonadotropin secretory dynamics during puberty in normal girls and boys. J Clin Endocrinol Metab 1990;71:1251-8.
33. Marshall JC, McCartney CR, Prendergast KA, Chhabra SK, Chopra C. Neuroendocrine connections in PCOS. In: Filicoro M, editor. Updates in infertility treatment 2004. Marco Island, Florida: Medimond; 2005.
34. Boyar RM, Ramsey J, Chipman J, Fevre M, Madden J, Marks JF. Luteinizing hormone and follicle-stimulating hormone secretory dynamics in Turner's syndrome. J Clin Endocrinol Metab 1978;47:1078-83.
35. South SA, Yankov VI, Evans WS. Normal reproductive neuroendocrinology in the female. Endocrinol Metab Clin North Am 1993;22:1-28.
36. Marshall JC, Eagleson CA. Neuroendocrine aspects of polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999;28:295-324.
37. Ross JL, Loriaux DL, Cutler GH Jr. Developmental changes in neuroendocrine regulation of gonadotropin secretion in gonadal dysgenesis. J Clin Endocrinol Metab 1983;57:288-93.
38. Speroff L, Fritz M. Clinical gynecologic endocrinology and infertility. 7th ed. Philadelphia. PA: Lippincott Williams & Wilkins; 2005.
39. Roberts V, Meunier H, Vaughan J, Rivier J, Rivier C, Vale W et al. Production and regulation of inhibin subunits in pituitary gonadotropes. Endocrinology 1989;124:552-4.
40. Blumenfeld Z, Ritter M. Inhibin, activin, and follistatin in human fetal pituitary and gonadal physiology. Ann N Y Acad Sci 2001;943:34-48.
41. Norwitz ER, Xu S, Jeong KH, Bedecarrats GY, Winebrenner LD, Chin WW et al. Activin A augments GnRH-mediated transcriptional activation of the mouse GnRH receptor gene. Endocrinology 2002;143:985-97.
42. Bilezikjian LM, Corrigan AZ, Blount AL, Vale WW. Pituitary follistatin and inhibin subunit messenger ribonucleic acid levels are differentially regulated by local and hormonal factors. Endocrinology 1996;137: 4277-84.
43. Bauer-Dantoin AC, Weiss J, Jameson JL. Roles of estrogen, progesterone, and gonadotropin-releasing hormone (GnRH) in the control of pituitary GnRH receptor gene expression at the time of the preovulatory gonadotropin surges. Endocrinology 1995;136:1014-9.
44. Burger, L.L., et al., GnRH pulse frequency modulation of gonadotropin subunit gene transcription in normal gonadotropes-assessment by primary transcript assay provides evidence for roles of GnRH and follistatin. Endocrinology, 2002, 143(9): p. 3243-9.
45. Besecke LM, Guendner MJ, Schneyer AL, Bauer-Dantoin AC, Jameson JL, Weiss J. Gonadotropin-releasing hormone regulates follicle-stimulating hormone-beta gene expression through an activin/follistatin autocrine or paracrine loop. Endocrinology 1996;137:3667-73.
46. 4n. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003;9: 505-14.
47. Fauser BC, Pache TD, Lamberts SW, Hop WC, de Jong FH, Dahl KD. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease. J Clin Endocrinol Metab 1991;73:811-7.
48. Waldstreicher J, Santoro NF, Hall JE, Filicori M, Crowley WF Jr. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization. J Clin Endocrinol Metab 1988;66:105-72.
49. van Santbrink EJ, Hop WC, Fauser BC. Classification of normogonadotropic infertility, polycystic ovaries diagnosed by ultrasound versus endocrine characteristics of polycystic ovary syndrome. Fertil Steril 1997;67: 452-8.
50. Christman GM, Randolph JF, Kelch RP, Marshall JC. Reduction of gonadotropin-releasing hormone pulse frequency is associated with subsequent selective follicle-stimulating hormone secretion in women with polycystic ovarian disease. J Clin Endocrinol Metab 1991;72:1278-85.
51. Hayes FJ, Taylor AE, Martin KA, Hall JE. Use of a gonadotropin-releasing hormone antagonist as a physiologic probe in polycystic ovary syndrome: assessment of neuroendocrine and androgen dynamics. J Clin Endocrinol Metab 1998;83:2343-9.
52. Hall JE, Taylor AE, Hayes FJ, Crowley WF Jr. Insights into hypothalamic-pituitary dysfunction in polycystic ovary syndrome. J Endocrinol Invest 1998;21:602-11.
53. Smith PF, Frawley LS, Neill JD. Detection of LH release from individual pituitary cells by the reverse hemolytic plaque assay: estrogen increases the fraction of gonadotropes responding to GnRH. Endocrinology 1984;115:2484-6.
54. Yoshino K, Takahashi K, Shirai T, Nishigaki A, Araki Y, Kitao M. Changes in plasma catccholamines and pulsatile patterns of gonadotropin release in subjects with a normal ovulatory cycle and with polycystic ovary syndrome. Int J Fertil 1990;35:34-9.
55. Buvat J, Buvat-Herbaut M, Marcolin G, Racadot A, Fourlinnie JC, Beuscart R et al. A double blind controlled study of the hormonal and clinical effects of bromocriptine in the polycystic ovary syndrome. J Clin Endocrinol Metab 1986;63:119-24.
56. Barnes RB, Lobo RA. Central opioid activity in polycystic ovary syndrome with and without dopaminergic modulation. J Clin Endocrinol Metab 1985;61:779-82.
57. Barnes RH, Mileikowsky GN, Cha KY, Spencer CA, Lobo RA. Effects of dopamine and metoclopramide in polycystic ovary syndrome. J Clin Endocrinol Metab 1986;63:506-9.
58. Berga SL, Yen SS. Opioidergic regulation of LH pulsatility in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1989;30:177-84.
59. Lanzone A, Apa R. Fulghesu AM, Cutillo G. Caruso A, Mancuso S. Long-term naltrexone treatment normalizes the pituitary response to gonadotropin-releasing hormone in polycystic ovarian syndrome. Fertil Steril 1993;59:734-7.
60. Xu B, Sahu A, Kalra PS, Crowley WR, Kalra SP. Disinhibition from opioid influence augments hypothalamic neuropeptide Y (NPY) gene expression and pituitary luteinizing hormone release: effects of NPY messenger rihonucleic acid antisense oligodeoxynucleotides. Endocrinology 1996;157:78-84.
61. Schoemaker J. Neuroendocrine control in polycystic ovary-like syndrome. Gynecol Endocrinol 1991;5:277-88.
62. Venturoli S, Porcu E, Fabbri R, Magrini O, Gammi L, Paradisi R et al. Episodic pulsatile secretion of FSH, LH, prolactin, oestradiol, oestrone, and LH circadian variations in polycystic ovary syndrome. Clin Endocrinol (Oxf) 1988;28:93-107.
63. Murdoch AP, Diggle PJ, White MC, Kendall-Taylor P, Dunlop W. LH in polycystic ovary syndrome: reproducibility and pulsatile secretion. J Endocrinol 1989;121:185-91.
64. Schachter M, Balen AH, Patel A, Jacobs HS. Hypogonadotropic patients with ultrasonographically detected polycystic ovaries: endocrine response to pulsatile gonadotropin-releasing hormone. Gynecol Endocrinol 1996;10:327-35.
65. White D, Leigh A, Wilson C, Donaldson A, Franks S. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1995;42:475-81.
66. Prelevic GM, Wurzburger MI, Balint-Peric L, Nesic JS. Inhibitory effect of sandostatin on secretion of luteinising hormone and ovarian steroids in polycystic ovary syndrome. Lancet 1990;336:900-3.
67. Abdel Gadir A, Mowafi RS, Alnaser HM, Alrashid AH, Alonezi OM, Shaw RW. Ovarian electrocautery versus human menopausal gonadotrophins and pure follicle stimulating hormone therapy in the treatment of patients with polycystic ovarian disease. Clin Endocrinol (Oxf) 1990;33:585-92.
68. Rossmanith WG, Keckstein J, Spatzier K, Lauritzen C. The impact of ovarian laser surgery on the gonadotrophin secretion in women with polycystic ovarian disease. Clin Endocrinol (Oxf) 1991;34:223-30.
69. Dubourdieu S, Le Nestour E, Spitz IM, Charbonnel B, Bouchard P. The combination of gonadotrophin-releasing hormone (GnRH) antagonist and pulsatile GnRH normalizes luteinizing hormone secretion in polycystic ovarian disease but fails to induce follicular maturation. Hum Reprod 1993;8:2056-60.
70. Rosenthal IM, Refetoff S, Rich B, Barnes RB, Sunthornthepvarakul T, Parma J et al. Response to challenge with gonadotropin-releasing hormone agonist in a mother and her two sons with a constitutively activating mutation of the luteinizing hormone receptor: a clinical research center study. J Clin Endocrinol Metab 1996;81:3802-6.
71. Sopelak VM, Hodgen GD. Blockade of the estrogen-induced luteinizing hormone surge in monkeys: a non-steroidal, antigenic factor in porcine follicular fluid. Fertil Steril 1984;41:108-13.
72. Lockwood GM, Muttukrishna S, Groome NP, Matthews DR, Ledger WL. Mid-follicular phase pulses of inhibin B are absent in polycystic ovarian syndrome and are initiated by successful laparoscopic ovarian diathermy: a possible mechanism regulating emergence of the dominant follicle. J Clin Endocrinol Metab 1998;83:1730-5.
73. Lockwood GM. The role of inhibin in polycystic ovary syndrome. Hum Fertil (Camb) 2000;3:86-92.
74. Pigny P, Cortet-Rudelli C, Decanter C, Deroubaix D, Soudan B, Duhamel A et al. Serum levels of inhibins are differentially altered in patients with polycystic ovary syndrome: effects of being overweight and relevance to hyperandrogenism. Fertil Steril 2000;73:972-7.
75. Lambert-Messerlian G, Taylor A, Leykin L, Isaacson K, Toth T, Chang Y et al. Characterization of intrafollicular steroid hormones, inhibin, and follistatin in women with and without polycystic ovarian syndrome following gonadotropin hyperstimulation. Biol Reprod 1997;57:1211-6.
76. Adashi EY, Hsueh AJ, Yen SS. Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells. Endocrinology 1981;108:1441-9.
77. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev. 1999 Aug;20(4):535-82.
78. Dunaif A, Mandeli J, Fluhr H, Dobrjansky A. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome. J Clin Endocrinol Metab 1988;66:131-9.
79. Morales AJ, Laughlin GA, Butzow T, Maheshwari H, Baumann G, Yen SS. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab 1996;81:2854-64.
80. Eagleson CA, Bellows AB, Hu K, Gingrich MB, Marshall JC. Obese patients with polycystic ovary syndrome: evidence that metformin does not restore sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by ovarian steroids. J Clin Endocrinol Metab 2003;88:5158-62.
81. Taylor AE, McCourt B, Martin KA, Anderson EJ, Adams JM, Schoenfeld D et al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:2248-56.
82. Van Dam EW, Roelfsema F, Veldhuis JD, Helmerhorst FM, Frolich M, Meinders AE et al. Increase in daily LH secretion in response to short-term calorie restriction in obese women with PCOS. Am J Physiol Endocrinol Metab 2002;282:E865-72.
83. Ropelato MG, Garcia-Rudaz MC, Castro-Fernandez C, Ulloa-Aguirre A, Escobar ME, Barontini M et al. A preponderance of basic luteinizing hormone (LH) isoforms accompanies inappropriate hypersecretion of both basal and pulsatile LH in adolescents with polycystic ovarian syndrome. J Clin Endocrinol Metab 1999;84:4629-36.
84. Tapanainen JS, Koivunen R, Fauser BC, Taylor AE, Clayton RN, Rajkowa M et al. A new contributing factor to polycystic ovary syndrome: the genetic variant of luteinizing hormone. J Clin Endocrinol Metab 1999;84: 1711-5.
85. Balen AH, Conway GS, Kaltsas G, Techatrasak K, Manning PJ, West C et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod 1995;10:2107-11.
86. Rosenfield RL, Barnes RB, Cara JF, Lucky AW. Dysre-gulation of cytochrome P450c 17 alpha as the cause of polycystic ovarian syndrome. Fertil Steril 1990;53: 785-91.
87. Melrose P, Gross L. Steroid effects on the secretory modalities of gonadotropin-releasing hormone release. Endocrinology 1987;121:190-9.
88. Barnes RB, Rosenfield RL, Ehrmann DA, Cara JF, Cuttler L, Levitsky LI et al. Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. J Clin Endocrinol Metab 1994;79: 1328-33.
89. Dunaif A. Do androgens directly regulate gonadotropin secretion in the polycystic ovary syndrome? J Clin Endocrinol Metab 1986;63:215-21.
90. Daniels TL, Berga SL. Resistance of gonadotropin releasing hormone drive to sex steroid-induced suppression in hyperandrogenic anovulation. J Clin Endocrinol Metab 1997;82:4179-83.
91. Sir-Petermann, T, Rabenbauer B, Wildt L. The effect of flutamide on pulsatile gonadotrophin secretion in hyperandrogenaemic women. Hum Reprod 1993;8: 1807-12.
92. Eagleson CA, Gingrich MB, Pastor CL, Arora TK, Burt CM, Evans WS et al. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 2000;85:4047-52.
93. Hardie L, Trayhurn P, Abramovich D, Fowler P. Circulating leptin in women: a longitudinal study in the menstrual cycle and during pregnancy. Clin Endocrinol (Oxf) 1997;47:101-6.
94. Moschos S, Chan JL, Mantzoros CS. Leptin and reproduction: a review. Fertil Steril 2002;77:433-44.
95. Rouru J, Anttila L, Koskinen P, Penttila TA, Irjala K, Huupponen R et al. Serum leptin concentrations in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:1697-700.
96. Oksanen L, Tiitinen A, Kaprio J, Koistinen HA, Karonen S, Kontula K. No evidence for mutations of the leptin or leptin receptor genes in women with polycystic ovary syndrome. Mol Hum Reprod 2000;6:873-6.
97. Venturoli S, Porcu E, Fabbri R, Magrini O, Gammi L, Paradisi R et al. Longitudinal evaluation of the different gonadotropin pulsatile patterns in anovulatory cycles of young girls. J Clin Endocrinol Metab 1992;74: 836-41.
98. Apter D, Butzow T, Laughlin GA, Yen SS. Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: relevance to the developmental phase of poly cystic ovarian syndrome. J Clin Endocrinol Metab 1994;79:119-25.
99. Hall JE. Gonadotrophin secretion in PCOS. In: Filicoro M, editor. Updates in infertility treatment 2004. Marco Island, Florida; Medimond; 2005.